Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

Partnership to explore expanded cardiac screening, clinical research, and AI-assisted echocardiography in Costa Rica

Toronto, Ontario – April 1, 2026 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**") (**TSXV: VPT; OTC: VPTDF**), a leader in AI-assisted cardiac imaging solutions, today announced a collaboration with the **Health Division of the Montecristo Group** to explore new clinical pathways for the implementation of Ventripoint's VMS+™ cardiac imaging platform in Costa Rica.

The collaboration will focus on identifying opportunities to expand access to advanced cardiac diagnostics, including remote screening for congenital and structural heart disease, the integration of VMS+™ technology into clinical research and clinical trial programs, and broader deployment of VMS+™ AI-assisted echocardiography solutions for patients across Costa Rica. These initiatives aim to improve accuracy in heart monitoring while increasing access to modern diagnostic tools for both public and private healthcare systems.

Through this partnership, the organizations will explore how the VMS+™ system can support hospitals, physicians, and research organizations by assisting the accuracy of cardiac imaging and enabling earlier detection of heart conditions, particularly in underserved or remote communities.

"We are excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica," said **Hugh MacNaught, President & CEO of Ventripoint Diagnostics**. "Their strong healthcare network, commitment to affordable high-quality care, and passion for innovation make them an ideal partner as we work to expand access to advanced cardiac diagnostics and support clinical research opportunities in central America."

"*At the Metropolitano Research Institute, we are proud to serve as the research partner of Ventripoint Diagnostics in Costa Rica, leveraging our expertise in clinical research execution and large-scale screening deployment in Costa Rica. This partnership enables us to translate advanced AI-driven cardiac imaging into real-world impact by expanding early detection, improving diagnostic accuracy, and increasing access to high-quality cardiovascular care.*" ***Catalina Ulloa, Director, Metropolitano Research Institute, Hospital Metropolitano, Grupo Montecristo.***

The collaboration is expected to support research partnerships, technology deployment initiatives, and clinical trial (CRO) programs that incorporate VMS+ as an affordable advanced cardiac measurement tool that supports new care models and pathways.

About the Health Division of the Montecristo Group

The Health Division of the Montecristo Group is part of one of Costa Rica's leading corporate groups, focused on advancing healthcare access, innovation, and patient-centered medical services. Through a network of healthcare companies and medical facilities - including Hospital Metropolitano and other specialized health services - the division works to provide high-quality medical care, promote preventative health, and introduce innovative healthcare solutions that improve wellbeing for communities across Costa Rica and the region. (grupomontecristo.com)

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.